Virginia Retirement Systems ET AL Grows Position in Retrophin, Inc. (RTRX)

Virginia Retirement Systems ET AL raised its stake in Retrophin, Inc. (NASDAQ:RTRX) by 20.1% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 88,000 shares of the biopharmaceutical company’s stock after acquiring an additional 14,700 shares during the quarter. Virginia Retirement Systems ET AL owned approximately 0.22% of Retrophin worth $2,190,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in RTRX. SG Americas Securities LLC lifted its holdings in Retrophin by 1.8% in the second quarter. SG Americas Securities LLC now owns 8,167 shares of the biopharmaceutical company’s stock valued at $158,000 after acquiring an additional 146 shares during the period. Legal & General Group Plc lifted its holdings in Retrophin by 4.3% in the second quarter. Legal & General Group Plc now owns 8,664 shares of the biopharmaceutical company’s stock valued at $168,000 after acquiring an additional 355 shares during the period. Dynamic Technology Lab Private Ltd acquired a new position in Retrophin in the third quarter valued at approximately $212,000. GSA Capital Partners LLP acquired a new position in Retrophin in the second quarter valued at approximately $279,000. Finally, Voya Investment Management LLC lifted its holdings in Retrophin by 11.8% in the second quarter. Voya Investment Management LLC now owns 17,905 shares of the biopharmaceutical company’s stock valued at $347,000 after acquiring an additional 1,891 shares during the period.

Retrophin, Inc. (RTRX) opened at $21.52 on Tuesday. The company has a quick ratio of 3.83, a current ratio of 3.88 and a debt-to-equity ratio of 0.15. Retrophin, Inc. has a twelve month low of $15.55 and a twelve month high of $26.44.

Retrophin (NASDAQ:RTRX) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.21). The business had revenue of $40.34 million for the quarter, compared to analyst estimates of $40.51 million. Retrophin had a negative return on equity of 10.13% and a negative net margin of 33.79%. The company’s quarterly revenue was up 18.8% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.09) earnings per share. equities research analysts anticipate that Retrophin, Inc. will post -1.25 EPS for the current fiscal year.

RTRX has been the subject of a number of analyst reports. BMO Capital Markets reissued a “buy” rating and issued a $44.00 price target on shares of Retrophin in a report on Friday, October 6th. ValuEngine downgraded Retrophin from a “hold” rating to a “sell” rating in a report on Monday, November 20th. Zacks Investment Research downgraded Retrophin from a “hold” rating to a “strong sell” rating in a report on Tuesday, November 14th. Finally, BidaskClub raised Retrophin from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 24th. Two analysts have rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $36.00.

ILLEGAL ACTIVITY NOTICE: “Virginia Retirement Systems ET AL Grows Position in Retrophin, Inc. (RTRX)” was originally reported by Transcript Daily and is owned by of Transcript Daily. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://transcriptdaily.com/2017/12/05/virginia-retirement-systems-et-al-grows-position-in-retrophin-inc-rtrx.html.

Retrophin Profile

Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).

Institutional Ownership by Quarter for Retrophin (NASDAQ:RTRX)

Receive News & Ratings for Retrophin Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply